The Utility of CSF Biomarkers in Diagnosing Alzheimer’s Disease: A Thai Cohort Study
Open Access
- 1 January 2025
- journal article
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders Extra
- Vol. 15 (1) , 162-173
Abstract
Introduction: Cutoff values for cerebrospinal fluid biomarkers vary by analytic technique and population, which complicates the differentiation of Alzheimer’s disease (AD) from non-AD dementias. We aimed to establish local cerebrospinal fluid biomarker cutoffs within a Thai cohort. Materials and Methods: We recruited 68 patients with various forms of dementia from the Memory Clinic at Siriraj Hospital, Thailand. Each patient underwent clinical subtyping for dementia, and their cerebrospinal fluid levels of Aβ42, p-tau181, and t-tau were quantified using the Fujirebio INNOTEST ELISA. We then employed a data-driven approach, specifically a Z-score-based Gaussian Mixture Model, to define intersection cutoffs for Aβ42, p-tau181, t-tau, and the p-tau181/Aβ42 ratio. These established biomarker cutoffs were subsequently incorporated with clinical manifestations to refine the clinicobiological diagnoses. Results: Our study included 67 patients (mean age 65.5 ± 7.4 years, 61.2% female). Using a data-driven approach, we established the following CSF biomarker cutoffs for identifying AD in this Thai cohort: Aβ42 at 492.67 pg/mL, p-tau181 at 44.00 pg/mL, t-tau at 545.97 pg/mL, and the p-tau181/Aβ42 ratio at 0.057. After incorporating these CSF biomarker results with clinical profiles, the diagnoses changed in 17.9% of the patients. Conclusions: In this study, CSF cutoffs for differentiating AD from non-AD dementia were established through a data-driven approach, which has been demonstrated as a valid alternative methodology. The integration of clinical and biological profiles is paramount in achieving accurate dementia diagnoses.Keywords
This publication has 41 references indexed in Scilit:
- Classification of primary progressive aphasia and its variantsNeurology, 2011
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes ScoresArchives of Neurology, 2008
- Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementiaNeurobiology of Aging, 2008
- Fluctuations of CSF amyloid-β levelsNeurology, 2007
- Vascular dementiaNeurology, 1993
- Alzheimer's Disease: The Amyloid Cascade HypothesisScience, 1992
- Amyloid deposition as the central event in the aetiology of Alzheimer's diseaseTrends in Pharmacological Sciences, 1991
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982